key: cord-0957651-nfj1v72e authors: Liang, X.; Or, B.; Tsoi, M. F.; Cheung, C. L.; Cheung, B. M. title: Prevalence of Metabolic Syndrome in the United States National Health and Nutrition Examination Survey (NHANES) 2011-2018 date: 2021-04-23 journal: nan DOI: 10.1101/2021.04.21.21255850 sha: 2cf795c5a7e4828f5557ed9aa896e0e2b669913d doc_id: 957651 cord_uid: nfj1v72e Importance: Metabolic syndrome (MetS) is a cluster of risk factors presaging the development of cardiovascular diseases and diabetes. It is a risk factor for severe coronavirus disease 2019 (COVID-19). Objective: To estimate the prevalence of MetS in the US National Health and Nutrition Examination Survey (NHANES) 2011-2018. Design, Setting, and Participants: This cohort study included 22370 eligible participants aged [≥]20 years from the NHANES 2011-2018. Main Outcome and Measure: MetS was defined as the presence of at least three of these components: central obesity, reduced high-density lipoprotein, elevated triglycerides, elevated blood pressure and elevated fasting blood glucose. The prevalence of MetS was estimated taking into account the complex sampling. The time trend was evaluated using logistic regression. Annual percentage changes (APC) were used to measure the trends in MetS prevalence. Results: The prevalence of MetS was 36.2% (95% CI, 32.3-40.3), 34.8% (95% CI, 32.3-37.4), 39.9% (95% CI, 36.6-43.2) and 38.3% (95% CI, 35.3-41.3) in 2011-2, 2013-4, 2015-6, 2017-8, respectively (P for trend =.08). Among the MetS components, the prevalence of elevated glucose increased from 48.7% (95% CI, 45.9-51.5) in 2011-2 to 64.3% (95% CI, 61.0-67.4) in 2017-8 [P for trend <.001; APC=11.7, (95% CI, 3.5-21.0)]. The prevalence of MetS in non-Hispanic Asian increased from 21.8% (95% CI, 16.7-28.0) in 2011-2 to 31.2% (95% CI, 27.4-35.3) in 2017-8 [P for trend <.001; APC=14.6, (95% CI, 2.5-34.8)]. Conclusion and Relevance: The prevalence of MetS remained stable from 2011 to 2018, but increased among non-Hispanic Asians. Lifestyle modification is needed to prevent metabolic syndrome and the associated risks of diabetes and cardiovascular disease. Keywords: Metabolic syndrome, Prevalence, 2011-2018 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Metabolic syndrome (MetS) is a cluster of conditions comprising central obesity, elevated blood pressure, hyperglycemia, hypertriglyceridemia and reduced high-density lipoproteincholesterol (HDL) that are associated with the development of type 2 diabetes mellitus and cardiovascular disease. 1 In the National Cholesterol Education Program's Adult Treatment Panel III definition, a person with three or more criteria above is deemed to have MetS. 2 We and other groups have shown that MetS is also associated with hypertension, stroke, cancer and increased mortality. [3] [4] [5] Recent studies have revealed that MetS and its components are highly associated with the susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the severity of coronavirus disease 2019 (COVID-19). 6, 7 Therefore, diagnosing metabolic syndrome is clinically important because it prompts clinicians to look for the myriad of diseases associated with it, helps patients to understand the causes of their seemingly diverse ailments, and paves the way for the prevention of the complications of MetS, such as cardiovascular diseases, and severity of COVID-19, through pharmacologic and non-pharmacologic therapy. 8 At the societal level, the prevalence of MetS is an index of the cardiometabolic health of the population. In the US, it has been reported many times that the prevalence of diabetes has been increasing and has reached epidemic proportions. 9 Abdominal obesity, or central obesity, leads to a state of systemic inflammation and insulin resistance. It plays a major role in the pathogenesis of MetS. 10 Previous reports have highlighted a steady increase in the prevalence of MetS in the US. 11, 12 However, its prevalence appears to have reached a plateau in 2016, with no evidence of further increases. 13 The prevalence was 34%, 33%, and 34.7% in 1999-2006, 14 2003-2012, 15 and 2011-2016, 13 respectively. This may seem surprising against the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. background of an obesity and diabetes epidemic, which would be expected to increase the prevalence of MetS as they are components of the syndrome. 16 Socioeconomic status (SES), reflecting education, occupation and income, is known to be a powerful predictor of morbidity and mortality. 17 Previous studies have shown greater decline in the prevalence of obesity, diabetes and cardiovascular diseases among people of higher SES in the US. 18 The prevalence and time trends in MetS in people with different SES warrants investigation. Therefore, we used the latest figures up to 2018 to estimate the latest prevalence of MetS in US adults, and in gender, age, ethnic and socioeconomic subgroups. The US National Health and Nutrition Examination Survey (NHANES) is a continuous and longitudinal survey since 1999. It received ethical approval from the National Center for Health Statistics Ethics Review Board. Written consent was obtained from all adult subjects. A cross-sectional, stratified, multistage probability sampling method was used to obtain a nationally representative sample of the US population ≥ 20 years of age. Demographics, examination, questionnaire, and laboratory data covering the period 2011-2018 were extracted. 19 Pregnant women were excluded to reduce bias associated with weight, hypertension, and gestational diabetes. Self-reported race/ethnicity was categorized into the following subgroups: Hispanic, non-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Hispanic white, non-Hispanic black, non-Hispanic Asian, and 'other'. Hispanic race/ethnicity includes Mexican American and other Hispanic races. Other race/ethnicity includes other non-Hispanic races, including non-Hispanic multiracial. Educational level was categorized into four subgroups: less than 11th grade, high school, some college, and college or above. Institute). All analyses were 2-tailed, and P<0.05 was considered statistically significant. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255850 doi: medRxiv preprint We included 22370 adult participants [mean age 47.9 years (95% CI, 47.3-48.6), 48.6% (95% CI, 47.5-49.6) men] from the four most recent 2-year cycles of continuous NHANES (2011-2012, 2013-2014, 2014-2016, 2017-2018) . The percentage of adults that underwent an examination in these cycles was 69.5%, 68.5%, 58.7%, and 48.8%, respectively. 21 Their characteristics of participants included in this study by gender, age group, race/ethnicity and socioeconomic status are shown in Table 1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. High SES was associated with a low prevalence of MetS (Table 2) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. we estimate that about 93 million people had the metabolic syndrome in 2018, which exceeded the prevalence of 50 million in 1990, and 64 million in 2000. 22 We also investigated the prevalence of MetS in gender, age and ethnic subgroups. Older individuals have a higher prevalence of MetS due to the increase in the prevalence of hypertension and diabetes with age. 23, 24 The increased overall prevalence of MetS was to a large extent driven by the increased prevalence in MetS in this age group. As the elderly population increases, the number of people with MetS is set to increase. A study showed that only 20.4% of older US adults had satisfactory health metrics. 7 The increase in MetS and the associated increase in diabetes, hypertension and cardiovascular disease will increase the population disease burden in the coming years. 25 The rise in the prevalence of MetS in non-Hispanic Asians in the US should not be overlooked. Asian Americans are the fastest-growing racial-ethnic minority in the United States. In 2018, Asian Americans comprised 6.5% of the U.S. population. 26 Despite the seemingly low rate of obesity in Asian Americans, they are prone to MetS and type 2 diabetes for the same BMI as other ethnic groups. 27, 28 Conversely, non-Hispanic blacks in the US have relatively higher lean mass and lower fat mass. 29 The impact of high BMI on the development of diabetes and hypertension shows ethnic differences, with the greatest impact seen among Asians and the least impact among blacks. 30, 31 We observed that the prevalence of MetS decreased with elevated educational attainment and income. People of low SES were more likely to have MetS. Possible explanations might include unhealthy lifestyle, diet habits, and poorer access to healthcare. Those with lower SES tend to have an unhealthy lifestyle, including smoking and alcohol consumption which 1 1 could aggravate the potential risks of MetS. 32 People with low income might prefer higher energy density food at less cost, which results in higher energy intake and increased risk of obesity. 33 Obese and obesity are closely related to development of MetS. Low SES is also related to psychiatric illnesses which can also result in metabolic syndrome by inducing unhealthy behaviors such as alcohol consumption, smoking, poor diet, sleeping disorder and poor adherence to treatment. 34, 35 MetS is associated with severe COVID-19. 7 Nearly half of COVID-19 patients had a comorbidity such as hypertension and diabetes. 36 Obesity confers a 2.4-fold higher odds of developing severe pneumonia in COVID- 19. 37 The high prevalence of MetS in the US and its increasing trend are worrying, since it may suggest that a substantial proportion of the US population is at risk of COVID-19 and its complications. There are some limitations in this study that should be acknowledged. Firstly, the NHANES is a cross-sectional survey that collected data from different participants in each time interval failing to provide longitudinal follow-up data. Secondly, NHANES used a recall questionnaire for some variables, especially the antihypertension and anti-diabetes medications, prone to recall and response bias. Thirdly, the number of participants, especially with triglyceride and high-density lipoprotein cholesterol, is relatively small. The prevalence of MetS in the US has not increased significantly in 2011-8. It was 36.2% (95% (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. Therapeutics and receives funding from the foundation. No specific funding received for this study. None All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 23, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (7):1392-1398. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. a Mexican American or other Hispanic race. b Other non-Hispanic races, including non-Hispanic multiracial. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Development of diabetes in Chinese with the metabolic syndrome: a 6-year prospective study Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2) The cardiovascular continuum in Asia--a new paradigm for the metabolic syndrome Metabolic Syndrome and COVID-19 The Proportion of Adult Americans at Risk of Severe COVID-19 Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010 Abdominal obesity and metabolic syndrome All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Prevalence of metabolic syndrome and obesity-associated Trends in the Prevalence of Metabolic Syndrome in the United States Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006 Prevalence of the metabolic syndrome in the United States Pre-diabetes, metabolic syndrome, and cardiovascular risk Socioeconomic status and health: what we know and what we don't Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults National Health and Nutrition Examination Survey Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement NHANES: Response Rates and Population Totals Increasing prevalence of the metabolic syndrome All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255850 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255850 doi: medRxiv preprint 2 1 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255850 doi: medRxiv preprint 2 2 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 23, 2021. ; https://doi.org/10.1101/2021.04.21.21255850 doi: medRxiv preprint